Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLGT Fulgent Genetics	$21.77 +1.7%	$19.66	$14.57 ▼ $23.99	$666.36M	0.83	342,674 shs	190,521 shs
FTRE Fortrea	$8.34 +7.8%	$5.98	$3.97 ▼ $25.28	$756.82M	1.81	1.78 million shs	1.81 million shs
PNTG The Pennant Group	$25.17 +1.7%	$25.40	$21.18 ▼ $37.13	$869.93M	1.48	427,074 shs	278,322 shs
VMD Viemed Healthcare	$7.31 +3.7%	$6.74	$5.93 ▼ $9.81	$283.53M	1.33	349,086 shs	353,081 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLGT Fulgent Genetics	0.00%	+2.40%	+18.25%	+7.19%	-7.32%
FTRE Fortrea	0.00%	+3.73%	+28.11%	+105.42%	-62.35%
PNTG The Pennant Group	0.00%	-0.36%	+8.96%	-9.36%	-23.47%
VMD Viemed Healthcare	0.00%	+6.10%	+16.22%	+13.86%	+2.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FLGT Fulgent Genetics	3.6914 of 5 stars	2.3	1.0	4.1	3.2	3.3	0.6
FTRE Fortrea	3.8559 of 5 stars	4.1	3.0	0.0	2.7	1.7	1.9
PNTG The Pennant Group	3.8323 of 5 stars	3.3	5.0	0.0	2.1	2.5	1.9
VMD Viemed Healthcare	2.0514 of 5 stars	0.0	3.0	0.0	2.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FLGT Fulgent Genetics	2.67	Moderate Buy	$25.33	16.37% Upside
FTRE Fortrea	2.17	Hold	$12.22	46.55% Upside
PNTG The Pennant Group	2.60	Moderate Buy	$33.40	32.70% Upside
VMD Viemed Healthcare	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VMD, PNTG, FTRE, and FLGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	PNTG The Pennant Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $29.00
8/8/2025	FTRE Fortrea	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	In-Line ➝ In-Line	$5.00 ➝ $7.00
8/7/2025	FTRE Fortrea	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight	$5.00 ➝ $6.00
8/5/2025	FLGT Fulgent Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$20.00 ➝ $30.00
8/4/2025	FLGT Fulgent Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$23.00 ➝ $21.00
8/4/2025	FTRE Fortrea	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2025	FTRE Fortrea	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$7.00 ➝ $9.00
7/16/2025	PNTG The Pennant Group	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$32.00 ➝ $28.00
7/11/2025	FTRE Fortrea	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.00
7/9/2025	FTRE Fortrea	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$6.00 ➝ $5.00
6/10/2025	PNTG The Pennant Group	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$35.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FLGT Fulgent Genetics	$283.47M	2.35	N/A	N/A	$36.32 per share	0.60
FTRE Fortrea	$2.70B	0.28	$1.57 per share	5.30	$6.49 per share	1.29
PNTG The Pennant Group	$695.24M	1.25	$0.92 per share	27.30	$9.65 per share	2.61
VMD Viemed Healthcare	$224.26M	1.26	$0.94 per share	7.77	$3.65 per share	2.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FLGT Fulgent Genetics	-$42.71M	-$1.66	N/A	N/A	N/A	-16.83%	-2.26%	-2.10%	N/A
FTRE Fortrea	-$328.50M	-$11.38	N/A	6.52	N/A	-37.57%	5.25%	1.72%	N/A
PNTG The Pennant Group	$22.56M	$0.78	32.27	28.60	2.07	3.36%	9.85%	4.04%	11/5/2025 (Estimated)
VMD Viemed Healthcare	$11.27M	$0.34	21.50	∞	N/A	5.80%	10.38%	7.88%	11/5/2025 (Estimated)

Latest VMD, PNTG, FTRE, and FLGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	FTRE Fortrea	$0.06	$0.19	+$0.13	-$4.14	$631.61 million	$710.30 million
8/6/2025	Q2 2025	VMD Viemed Healthcare	$0.0850	$0.08	-$0.0050	$0.08	$63.50 million	$63.06 million
8/1/2025	Q2 2025	FLGT Fulgent Genetics	-$0.23	$0.07	+$0.30	-$0.62	$76.21 million	$81.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FLGT Fulgent Genetics	N/A	N/A	N/A	N/A	N/A
FTRE Fortrea	N/A	N/A	N/A	N/A	N/A
PNTG The Pennant Group	N/A	N/A	N/A	N/A	N/A
VMD Viemed Healthcare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FLGT Fulgent Genetics	N/A	6.01	6.01
FTRE Fortrea	1.87	1.02	1.02
PNTG The Pennant Group	0.11	1.21	1.21
VMD Viemed Healthcare	0.02	1.48	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FLGT Fulgent Genetics	48.06%
FTRE Fortrea	N/A
PNTG The Pennant Group	85.88%
VMD Viemed Healthcare	74.24%

Insider Ownership

Company	Insider Ownership
FLGT Fulgent Genetics	31.76%
FTRE Fortrea	0.38%
PNTG The Pennant Group	5.40%
VMD Viemed Healthcare	20.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FLGT Fulgent Genetics	1,313	30.61 million	20.89 million	Optionable
FTRE Fortrea	15,500	90.80 million	90.46 million	Optionable
PNTG The Pennant Group	7,000	34.56 million	32.70 million	Optionable
VMD Viemed Healthcare	1,179	38.79 million	31.03 million	Not Optionable

VMD, PNTG, FTRE, and FLGT Headlines

Recent News About These Companies

Jerome Cambre Sells 4,880 Shares of Viemed Healthcare, Inc. (NASDAQ:VMD) Stock

August 16, 2025 | marketbeat.com

Insider Selling: Viemed Healthcare, Inc. (NASDAQ:VMD) President Sells 50,090 Shares of Stock

August 15, 2025 | marketbeat.com

Michael Moore Sells 50,090 Shares of Viemed Healthcare, Inc. (NASDAQ:VMD) Stock

August 14, 2025 | insidertrades.com

Viemed Healthcare, Inc. (NASDAQ:VMD) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

Viemed Healthcare (NASDAQ:VMD) Posts Quarterly Earnings Results, Meets Estimates

August 10, 2025 | marketbeat.com

Viemed Healthcare, Inc. (VMD) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Viemed VMD Q2 2025 Earnings Call Transcript

August 7, 2025 | fool.com

Viemed (VMD) Q2 Revenue Rises 15%

August 6, 2025 | fool.com

Viemed Healthcare Achieves Record Q2 2025 Revenues and Expands Guidance

August 6, 2025 | msn.com

Viemed Healthcare, Inc.: Viemed Healthcare Announces Second Quarter 2025 Financial Results

August 6, 2025 | finanznachrichten.de

Viemed Healthcare Announces Second Quarter 2025 Financial Results

August 6, 2025 | accessnewswire.comA

GSA Capital Partners LLP Buys 124,731 Shares of Viemed Healthcare, Inc. (NASDAQ:VMD)

August 1, 2025 | marketbeat.com

Victory Capital Management Inc. Increases Stake in Viemed Healthcare, Inc. (NASDAQ:VMD)

July 31, 2025 | marketbeat.com

Viemed Healthcare Announces Second Quarter 2025 Earnings Conference Call Details

July 22, 2025 | accessnewswire.comA

Lafayette’s Viemed completes $26 million acquisition of Illinois medical equipment firm

July 9, 2025 | theadvertiser.comT

Viemed officially adds Lehan’s to family

July 7, 2025 | hmenews.comH

Viemed Completes Acquisition of Lehan's Medical Equipment Anticipates Updating its Full Year 2025 Outlook for the Acquisition with Second Quarter 2025 Financial Results

July 2, 2025 | accessnewswire.comA

Insider Selling: Viemed Healthcare, Inc. (NASDAQ:VMD) Director Sells 8,852 Shares of Stock

July 1, 2025 | insidertrades.com

Viemed Healthcare: Getting More Air

June 25, 2025 | seekingalpha.com

viemed healthcare shareholders approve key amendments and director elections

June 7, 2025 | investing.com

Viemed Healthcare, Inc. (VMD): A Bull Case Theory

May 14, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VMD, PNTG, FTRE, and FLGT Company Descriptions

Fulgent Genetics NASDAQ:FLGT

$21.77 +0.37 (+1.73%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$21.81 +0.04 (+0.18%)

As of 08/22/2025 05:50 PM Eastern

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Fortrea NASDAQ:FTRE

$8.34 +0.60 (+7.75%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.36 +0.02 (+0.18%)

As of 08/22/2025 07:33 PM Eastern

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

The Pennant Group NASDAQ:PNTG

$25.17 +0.42 (+1.70%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$24.91 -0.26 (-1.05%)

As of 08/22/2025 07:29 PM Eastern

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

Viemed Healthcare NASDAQ:VMD

$7.31 +0.26 (+3.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.32 +0.01 (+0.07%)

As of 08/22/2025 07:08 PM Eastern

Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time